COVID-19
Last updated: November 2023. The page will be updated annually
It looks like you are using an older version of Internet Explorer which is not supported. We advise that you update your browser to the latest version of Microsoft Edge, or consider using other browsers such as Chrome, Firefox or Safari.
Last updated: November 2023. The page will be updated annually
Novartis routinely monitors cases of COVID-19 in patients on therapy with siponimod. Based on the totality of data available from the COVID-19 case reports in the clinical trials and postmarketing setting as well as comprehensive data analysis by MS Data Alliance GDSI1
As of March 25, 2023, with an exposure of over >31,187 patient-years, a total of 579 cases, either confirmed**(n=571) or suspected^ (n=8) COVID-19 were identified in patients receiving siponimod treatment in the postmarketing setting.2 There were 175 cases from ongoing clinical trials, with 173 confirmed** and two suspected^ cases as of March 25, 2023.3 |
Clinical trials and Open-label extension
COVID-19: Confirmed cases2,3
Novartis routinely monitors COVID-19 vaccine clinical response in patients on therapy with siponimod received from clinical trials or from the post marketing setting.
In clinical trials, of the 357 fully vaccinated patients (an additional 50 patients received partial dose), 88 patients had breakthrough COVID-19 infectionʆ (i.e., ≥2 weeks after 2nd dose of vaccine, or ≥ 2 weeks after one dose of a single dose regimen). This includes one patient who had a fatal outcome, two cases reported outcome as not recovered and 85 patients outcome is reported as recovered.
This website is for non-promotional purposes and is intended for providing
safety information for healthcare professionals (HCPs) Only
Please confirm that you are an HCP
For HCPs: Information on this website is not country specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.
For non-HCPs / patients: This safety website is available for HCPs only
The Pregnancy outcome Intensive Monitoring (PRIM) program is based on enhanced pharmacovigilance of the Novartis spontaneous reporting system. PRIM is an adverse event outcomes intensive monitoring program to collect information (targeted follow-up checklists) about pregnancy in patients exposed to siponimod immediately before or during pregnancy and infant outcomes 12 months after delivery.